A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling

AIM: Use of immunomodulating therapeutics for immune‐mediated inflammatory diseases may cause disease‐drug‐drug interactions (DDDIs) by reversing inflammation‐driven alterations in the metabolic capacity of cytochrome P450 enzymes. European Medicine Agency (EMA) and US Food and Drug Administration (...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Laura M., Klomp, Sylvia D., Treijtel, Nicoline, Rissmann, Robert, Swen, Jesse J., Manson, Martijn L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Meta‐analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545038/
https://www.ncbi.nlm.nih.gov/pubmed/35484780
http://dx.doi.org/10.1111/bcp.15372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545038/
https://www.ncbi.nlm.nih.gov/pubmed/35484780
http://dx.doi.org/10.1111/bcp.15372

Ejemplares similares